Home > Boards > US OTC > Medical - Drugs > Tenax Therapeutics, Inc. (TENX)

We are all pretty much relying on the

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
RisingMT Member Profile
 
Followed By 4
Posts 636
Boards Moderated 0
Alias Born 03/17/17
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 6/14/2019 4:34:25 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/15/2019 4:54:55 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/22/2019 4:31:34 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/19/2019 4:32:33 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/18/2019 4:34:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/18/2019 4:34:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/18/2019 4:33:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/18/2019 4:33:39 PM
Annual Report (10-k) Edgar (US Regulatory) - 4/1/2019 4:33:58 PM
Tenax Therapeutics Enrolls First Patient for Phase 2 Pulmonary Hypertension Clinical Trial Business Wire - 3/11/2019 8:30:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2019 11:37:54 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/12/2019 5:36:33 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/5/2019 2:08:30 PM
Tenax Therapeutics to Present at 2019 BIO CEO & Investor Conference Business Wire - 2/4/2019 8:30:00 AM
Tenax Therapeutics to Present at Biotech Showcase Investor Conference Business Wire - 1/4/2019 8:30:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 12/14/2018 3:45:38 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/11/2018 4:07:59 PM
Tenax Therapeutics Announces Closing of $10 Million Underwritten Offering Business Wire - 12/11/2018 4:00:00 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 12/10/2018 6:01:46 AM
Prospectus Filed Pursuant to Rule 424(b)(4) (424b4) Edgar (US Regulatory) - 12/7/2018 5:12:47 PM
Tenax Therapeutics Announces Pricing of $10 Million Underwritten Offering Business Wire - 12/7/2018 1:02:00 PM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 12/6/2018 8:33:10 AM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 12/3/2018 5:28:07 PM
Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp) Edgar (US Regulatory) - 11/20/2018 5:06:34 PM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 11/20/2018 4:33:39 PM
RisingMT   Sunday, 04/07/19 01:06:04 PM
Re: None
Post # of 7855 
We are all pretty much relying on the success of the clinical trials on the efficacy of levosimendan for patients with PH-HFpEF. Seems if the trial fails, this business will have nothing else and will fall to bankruptcy.

I hope their team is more suited for the job that needs to be done this time. It’s crazy how they managed to screw up the previous trial when levos is approved in 60 other countries.

Anyone know how long these trials usually take to complete?

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist